Format

Send to

Choose Destination
See comment in PubMed Commons below
Heart Lung. 2012 Sep-Oct;41(5):456-62. doi: 10.1016/j.hrtlng.2012.04.007. Epub 2012 May 30.

The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention.

Author information

  • 1Department of Integrated ICU, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, PR China.

Abstract

BACKGROUND:

This study was designed to evaluate the value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).

METHODS:

A total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI. Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 (≥1.35 mg/L).

RESULTS:

After a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001). The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events. The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001).

CONCLUSION:

High plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with ACS treated with PCI.

Crown Copyright © 2012. Published by Mosby, Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk